What question did this study set out to answer?

The study aims to explore the molecular mechanisms and biomarker profiles in malignant hypertension to understand organ damage.

Circulating Biomarkers in Malignant Hypertension: Insights From the Ivama Study

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial identifies specific biomarkers linked to organ damage in malignant hypertension, suggesting distinct biological pathways.

The study aims to explore the molecular mechanisms and biomarker profiles in malignant hypertension to understand organ damage.
Multicenter, prospective case-control study involving 30 malignant hypertension patients and 15 controls.
Blood and urine samples were collected at baseline and one month later to assess various biomarkers.
Statistical analysis included repeated measures ANOVA, PCA, MFA, and multinomial logistic regression.
MHT patients exhibited significantly higher SBP and DBP compared to controls, with notable organ damage.
Elevated biomarkers (ANGPT2, ANGPTL4, GAL-1, TREM-1, VEGFD, IL1-RA, ET-1) correlated strongly with organ injury parameters.
Multivariate analysis revealed VEGFD, GAL-1, TREM-1, IL33R, and ANGPT2 as significant predictors of organ damage clusters.

Boulestre et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial identifies specific biomarkers linked to organ damage in malignant hypertension, suggesting distinct biological pathways.